EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Top Cited Papers
- 1 January 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 13 (1), 33-42
- https://doi.org/10.1016/s1470-2045(11)70318-7
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX studyThe Lancet Oncology, 2011
- Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?Journal of Clinical Oncology, 2010
- Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern PlotJournal of Clinical Oncology, 2010
- Biomarkers in NSCLC for selecting cetuximab therapyNature Reviews Clinical Oncology, 2010
- Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization studyLung Cancer, 2010
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialThe Lancet, 2009
- Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptorCancer Science, 2007
- Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)Clinical Cancer Research, 2004
- Patterns of treatment effects in subsets of patients in clinical trialsBiostatistics, 2004
- A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the dataStatistics in Medicine, 2000